Indivior settles FTC complaint that it blocked generic competition to Suboxone

1174
SHARE

Last year, Reckitt Benckiser agreed to pay $700 million to settle a six qui tam lawsuit filed by Pennsylvania and other states in connection with its improper marketing of Suboxone Sublingual Tablet.